Rolf H. Günther

Managing Director, RHG Life Science Consulting

Frankfurt Rhine-Main Metropolitan Area

About

An accomplished, highly seasoned executive with over 25 years of pharmaceutical industry experience and an extensive background in drug development, biologics and specialty pharmaceuticals. A leader with a successful track record in both big pharma and biotech companies to develop corporate strategies and to build highly motivated teams focused on achieving company goals. Outstanding knowledge and proven experience in antibody, protein and small molecule drug early and late stage product development.

Experience

  • General Manager at Selbstständig
    Nov 2015 - Present · 10 yrs 9 mos

  • CEO at Bicycle Therapeutics LTD
    Apr 2012 - Sep 2015 · 3 yrs 6 mos

    • Defining and implementing the product development strategy in oncology • Successful closing of a US $ 32m financing round series A with top tier European and US investors. • Strengthening the management team by hiring CSO, President and CBO and CMO • Building a pipeline of 6 oncology candidates, 2 for own risk development, 4 for partnering • Leading the IND enabling preclinical development of 2 candidates • Successful partnering of preclinical non-oncology programme

  • CEO and COO at Affimed Therapeutics AG
    Sep 2004 - Mar 2012 · 7 yrs 7 mos

    • Defining the new strategic direction towards a product development company and leading the implementation • Guiding the company as it refined its product pipeline • Filling key executive positions in Finance, Business Development and Product Development • Implementing a lean and efficient infrastructure for product development and manufacturing • Leading pre-clinical development and GMP production internal product candidates into the clinical phase • Driving clinical development in the EU and US with successful clinical proof-of-concept of the lead candidate • Successful closing of 3 large financing rounds series B and series C with top tier European and US investors with a total volume of US $ 50m. • Successful spin off of antibody discovery into a daughter company; achieved profitability after one year

  • Aventis Behring (9 yrs 1 mo)
    • Vice President and General Manager
      2002 - 2004 · 2 yrs

      Business Unit Critical Care

    • Vice President
      1995 - 2002 · 7 yrs

      Head of Global Clinical R&D

  • Vice President at Behringwerke AG
    1990 - 1995 · 5 yrs

    Head of Clinical R&D